Subcutaneous abdominal injections of the experimental monoclonal antibody nemolizumab produced significant improvement in patients with atopic dermatitis and moderate-to-severe pruritus, a study shows.

The improvements were seen in several measures of disease severity during the 16-week, phase 3 double-blinded trial carried out in 215 Japanese volunteers, all aged 13 or older.